Tarsus Pharmaceuticals 

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$102,660
$78,335
$66,408
$48,118
Gross Profit
96,423
73,124
61,482
44,876
EBITDA
-17,647
-26,280
-20,369
-20,675
EBIT
-18,100
-27,333
-20,801
-20,959
Net Income
-20,340
-25,120
-23,113
-23,420
Net Change In Cash
102,660
78,335
66,408
48,118
Free Cash Flow
-30,388
-21,241
-27,254
-8,934
Cash
96,648
175,787
94,819
176,210
Basic Shares
42,360
39,345
38,561
38,382

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$182,953
$17,447
$25,816
$57,027
Gross Profit
170,127
15,854
24,861
54,952
EBITDA
-106,480
-131,670
-59,107
-13,166
EBIT
-107,705
-132,547
-59,896
-13,772
Net Income
-115,554
-135,893
-62,091
-13,827
Net Change In Cash
182,953
17,447
25,816
57,027
Cost of Revenue
-99,672
3,183
Free Cash Flow
-84,594
-122,995
-49,536
3,162
Cash
94,819
224,947
71,660
171,332
Basic Shares
37,605
29,383
24,619
20,554

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
-$0.48
2025-03-31
-$0.64
2024-12-31
-$0.60